A Form 4 filed on August 14, 2026 discloses that John Kiely, a director of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX), sold 50,000 shares and donated 10,000 shares of Class A Common Stock on August 13, 2026.

Key Highlights

  • Sale transaction: John Kiely disposed of 50,000 shares of Class A Common Stock on August 13, 2026 at a weighted average price of $17.64 per share.
  • Price range: The 50,000 shares were sold in multiple transactions at prices ranging from $17.26 to $17.88 per share, inclusive.
  • Charitable donation: Kiely donated 10,000 shares of Class A Common Stock to a donor advised fund at $0 on August 13, 2026.
  • Post-transaction ownership: Following both transactions, Kiely directly beneficially owns 200,252 shares of Class A Common Stock.
  • Reporting person role: John Kiely is identified as a Director of Amneal Pharmaceuticals, Inc.

John Kiely's August 2026 Share Sale and Donation at Amneal Pharmaceuticals

According to the filing, John Kiely, a director of Amneal Pharmaceuticals, Inc., executed two transactions involving the company's Class A Common Stock on August 13, 2026. The first was a sale of 50,000 shares coded "S," with a weighted average price of $17.64 per share. The filing notes that these shares were sold across multiple transactions at prices ranging from $17.26 to $17.88 per share, inclusive, and that Kiely undertakes to provide full information regarding the number of shares sold at each separate price upon request by the company or SEC staff.

The second transaction, coded "G," involved the disposition of 10,000 shares at $0, which the filing describes as a charitable donation of common stock to a donor advised fund. Following both the sale and the donation, Kiely's directly held beneficial ownership of Class A Common Stock stood at 200,252 shares, according to the filing. Both ownership positions are reported as held directly.

The Form 4 was signed by Denis Butkovic as Attorney-in-Fact on August 14, 2026, and was filed as an individual, single-reporting-person filing. No derivative securities transactions were reported.

What Was Disclosed

Amneal Pharmaceuticals director John Kiely reported the sale of 50,000 Class A Common Stock shares at a weighted average of $17.64 and a charitable donation of 10,000 shares to a donor advised fund, leaving him with 200,252 directly held shares.